NovoCure reported a solid jump in revenue, but earnings fell short due to rising costs and adoption challenges.

瑞士巴尔 - 尽管收入超出预期，但由于第四季度收益未能达到分析师预期，肿瘤治疗公司Novocure（NASDAQ:NVCR）股价下跌6.3%。该公司在将其肿瘤治疗场（TTFields）疗法扩展到新适应症方面取得进展，但投资者似乎对超出预期的亏损表示担忧。

NovoCure remains a strong buy with robust earnings, growth in cancer treatments, and significant upside potential to Wall ...

NovoCure's FDA approvals face adoption struggles despite growth. Read why NVCR stock may decline with slow indication ...

Welcome to the NovoCure fourth-quarter 2024 earnings conference call. [Operator instructions] Please be advised that today's ...

NovoCure Limited (NASDAQ:NVCR – Get Free Report) shares gapped down before the market opened on Thursday after the company announced weaker than expected quarterly earnings. The stock had previously ...

英为财情Investing.com - Novocure (NASDAQ: NVCR )星期四发布了第四季度的财报，数据显示，公司营收高于分析师的预期，每股收益低于分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.61，总营收为$161.26M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$153.04M，每股收益为$-0.36.

NovoCure Ltd. (($NVCR)) has held its Q4 earnings call. Read on for the main highlights of the call. NovoCure’s recent earnings call showcased a ...

While the top- and bottom-line numbers for NovoCure (NVCR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics ...

NovoCure's revenue increased 21% year over year, reaching $161.3 million in Q4 2024, matching analyst estimates. An EPS loss of $0.61 was significantly worse than the estimated $0.34 loss due to ...

NovoCure (NVCR) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.45 per share a year ago. These figures are ...

NovoCure (NVCR) reported $161.27 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 20.6%. EPS of -$0.61 for the same period compares to -$0.45 a ...